Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Clinical Trial
. 2018 Jan;18(1):106-112.
doi: 10.1038/tpj.2016.67. Epub 2016 Sep 27.

Genome-wide Association Study Identifies Pharmacogenomic Loci Linked With Specific Antihypertensive Drug Treatment and New-Onset Diabetes

Free PMC article
Clinical Trial

Genome-wide Association Study Identifies Pharmacogenomic Loci Linked With Specific Antihypertensive Drug Treatment and New-Onset Diabetes

S-W Chang et al. Pharmacogenomics J. .
Free PMC article


We conducted a discovery genome-wide association study with expression quantitative trait loci (eQTL) annotation of new-onset diabetes (NOD) among European Americans, who were exposed to a calcium channel blocker-based strategy (CCB strategy) or a β-blocker-based strategy (β-blocker strategy) in the INternational VErapamil SR Trandolapril STudy. Replication of the top signal from the SNP*treatment interaction analysis was attempted in Hispanic and African Americans, and a joint meta-analysis was performed (total 334 NOD cases and 806 matched controls). PLEKHH2 rs11124945 at 2p21 interacted with antihypertensive exposure for NOD (meta-analysis P=5.3 × 10-8). rs11124945 G allele carriers had lower odds for NOD when exposed to the β-blocker strategy compared with the CCB strategy (Odds ratio OR=0.38(0.24-0.60), P=4.0 × 10-5), whereas A/A homozygotes exposed to the β-blocker strategy had increased odds for NOD compared with the CCB strategy (OR=2.02(1.39-2.92), P=2.0 × 10-4). eQTL annotation of the 2p21 locus provides functional support for regulating gene expression.


Figure 1
Figure 1. Regional plot at chromosome 2p21 locus for new-onset diabetes (NOD) association in INVEST European Americans
Regional SNP*Treatment interaction analysis results (−log p-value) are plotted for INVEST European Americans. Figure is generated using LocusZoom. The diamond-shaped dot represent the SNP with lowest interaction p-value in the loci. The lower panel demonstrated the RefSeq genes.
Figure 2
Figure 2. Forest plot of the PLEKHH2 rs11124945 pharmacogenomics association with New-onset Diabetes (NOD)
This figure shows PLEKHH2 rs11124945 genotypes specific odds ratio and 95% confidence interval for NOD in each race groups and combined meta-analysis from the INVEST NOD case-control study (n = 1140). Point estimate was reported under a dominant genetic model for each genotype group, which represents higher risk for NOD in the CCB strategy or the β-blocker strategy. Interaction p-values for Hispanics and African Americans are one-sided.

Similar articles

See all similar articles


    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322. - PubMed
    1. WHO . Global status report on noncommunicable diseases 2014. World Health Organization; Switzerland: 2014.
    1. Weycker D, Nichols GA, O'Keeffe-Rosetti M, Edelsberg J, Vincze G, Khan ZM, et al. Excess risk of diabetes in persons with hypertension. J Diabetes Complications. 2009;23(5):330–336. - PubMed
    1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997. - PubMed
    1. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008;31(5):982–988. - PubMed

Publication types

MeSH terms